Announcement PDF ASX ANNOUNCEMENT 8 August 2023 Biome Australia launches 3 new Activated Probiotic products ● Biome has successfully launched three new clinically-trialled products into its Activated Probiotics® range ● Biome Dental™, Biome Lax™ and Biome Recovery™ are now available to Biome’s distribution network of over 4000 community pharmacies and independent health practitioners ● Biome aims to use these new products to further develop its relationships with and expand its network of healthcare practitioners, and improve patients’ quality of life Microbiome health company Biome Australia Limited (ASX: BIO) (‘Biome’ or ‘the company’) is pleased to announce it has successfully launched three new condition-specific live biotherapeutic products, Biome DentalTM Probiotic, Biome LaxTM Probiotic and Biome RecoveryTM Probiotic. ● ● ● Biome DentalTM Probiotic: to help support dental health and a healthy oral microbiome Biome LaxTM Probiotic: to help promote bowel regularity and reduce occurrence of bloating Biome RecoveryTM Probiotic: to help improve muscle recovery time and reduce mild muscle inflammation Biome DentalTM The benefits of Biome DentalTM Probiotic are supported by ten1-10 published clinical trials on oral health, including dental plaque and gum health. In one of these studies, the effect of Biome DentalTM was compared to placebo and chlorhexidine mouthwash in 60 healthy children. After 14 days of intake, the average dental plaque score and gingival index (a measure of poor gum health) were 71% and 73% lower in the Biome DentalTM group compared to placebo (p<0.05)8. Biome LaxTM The benefits of Biome LaxTM Probiotic are supported by a randomised, double-blind, placebo-controlled trial. In this study, administration of Biome LaxTM for 30 days was found to improve bowel regularity by 37%, reduce the level of discomfort associated with bowel movements by 67% and improve bloating by 52%, which were statistically significant when compared to placebo (p<0.001)11. Biome RecoveryTM The benefits of Biome RecoveryTM Probiotic are supported by a randomised, double-blind, placebo-controlled trial. This study found that after 21 days of supplementation, the probiotic formulation in Biome Recovery™ Probiotic helped to reduce mild muscle inflammation, improve muscle recovery time and support physical performance in back-to-back exercises12. These products have now been made available to Biome’s network of health retail partners and practitioner distributors which include over 4000 community pharmacies and independent health practitioners. First shipments have been sent to fill initial pre-launch orders from Biome’s wholesale customers. This includes pharmacy distributors Symbion and API as well as independent health practitioner distributors Oborne Health, Vital.ly, Rener Health, and Ariya. Biome Australia Managing Director and Founder Blair Norfolk said: “The release of these three new products under the Activated Probiotics® brand, including the first of Biome’s products to target dental health, provides significant commercial opportunities for the company to develop its relationships with dental practitioners, expanding its network of healthcare practitioners. Similarly, Biome Lax and Recovery open up new patient segments while supporting Biome’s mission to help improve health outcomes and quality of life for patients taking our products.” 1 References 1. Jindal, G., Pandey, R. K., Agarwal, J., & Singh, M. (2011). A comparative evaluation of probiotics on salivary mutans streptococci counts in Indian children. European Archives of Paediatric Dentistry, 12(4), 211–215. 2. Jothika, M., Vanajassun, Pp., & Someshwar, B. (2015). Effectiveness of probiotic, chlorhexidine and fluoride mouthwash against Streptococcus mutans - Randomized, single-blind, in vivo study. Journal of International Society of Preventive and Community Dentistry, 5(7), 44. 3. Doppalapudi, R., Vundavalli, S., & Prabhat, M. P. V. (2020). Effect of probiotic bacteria on oral Candida in head‑ and neck‑radiotherapy patients: A randomized clinical trial. Journal of Cancer Research and Therapeutics, 16, 470–477. 4. Thakkar, P. K., Imranulla, M., Kumar, P. G. N., Prashant, G. M., Sakeenabi, B., & Sushanth, V. H. (2013). Effect of probiotic mouthrinse on dental plaque accumulation: A randomized controlled trial. Dentistry and Medical Research|, 1(1), 7–12. 5. Deshmukh, M. A., Dodamani, A. S., Karibasappa, G., Khairnar, M. R., Naik, R. G., & Jadhav, H. C. (2017). Comparative evaluation of the efficacy of probiotic, herbal and chlorhexidine mouthwash on gingival health: A randomized clinical trial. Journal of Clinical and Diagnostic Research, 11(3), ZC13–ZC16. 6. Purunaik, S., Thippeswamy, H. M., & Chavan, S. S. (2014). To Evaluate the Effect of Probiotic Mouthrinse on Plaque and Gingivitis among 15-16 Year Old School Children of Mysore City, India - Randomised Controlled Trial. Global Journal of Medical Research, 14(4), 9–14. 7. Jindal, V., Mahajan, N., Goel, A., Kaur, R., Mahajan, A., & Malhotra, P. (2017). Clinical efficacy of probiotic mouthwash in the treatment of gingivitis patients in Himachal population. Journal of the International Clinical Dental Research Organization, 9(1), 41. 8. Sharma, P., Datta, G., Gandhi, K., & Kumar, D. (2019). A comparative evaluation of efficacy of probiotic and chlorhexidine mouthrinses on gingival health and plaque accumulation in 6-9 year old children. International Journal of Applied Dental Sciences, 5(1), 156–162. 9. Ranjith, et al. 2022. Probiotic mouthwash as an adjunct to mechanical therapy in the treatment of stage II periodontitis: A randomized controlled clinical trial. Internati onal Journal of Dental Hygiene,20(2), pp.415-421. 10. Manikandan, S., Behera, S., Karthikeyan, R., Niranjana, A., Bharathan, R., & Mohammed, O. B. (2020). Effect of green tea extract mouthrinse and probiotic mouthrinse on salivary pH in a group of schoolchildren: An in vivo study. Journal of Pharmacy And Bioallied Sciences, 12(5), 404. 11. del Piano, M., Carmagnola, S., Anderloni, A., Andorno, S., Ballar̈, M., Balzarini, M., Montino, F., Orsello, M., Pagliarulo, M., Sartori, M., Tari, R., Sforza, F., & Capurso, L. (2010). The use of probiotics in healthy volunteers with evacuation disorders and hard stools: A double-blind, randomised, placebo-controlled study. Journal of Clinical Gastroenterology, 44, 30–34. 12. Jäger, R., Purpura, M., Stone, J. D., Turner, S. M., Anzalone, A. J., Eimerbrink, M. J., Pane, M., Amoruso, A., Rowlands, D. S., & Oliver, J. M. (2016). Probiotic Streptococcus thermophilus FP4 and Bifidobacterium breve BR03 supplementation attenuates performance and range-of-motion decrements following muscle damaging exercise. Nutrients, 8(10), 1–11. –ENDS– Approved for release by the Biome Australia board of directors. About Biome Australia Limited Biome Australia develops, licenses, commercialises and markets innovative, evidence-based live biotherapeutics (probiotics) and complementary medicines, many of which are supported by clinical research. Biome aims to improve health outcomes and quality of life, and make its products accessible to all. Incorporated in Australia in 2018, Biome distributes locally and abroad. In partnership with some of the world's leading organisations in microbiome research and development, Biome produced several unique live biotherapeutic (probiotic) products with innovative delivery technologies that improve their stability and efficacy to create its flagship range of complementary medicines: Activated Probiotics®. Supported by clinical research, including randomised double-blind placebo-controlled trials, Activated Probiotics help prevent and support the management of various health concerns, including low mood and sleep, bone health, iron malabsorption, mild eczema and IBS. Through practitioner-only distribution, Biome is committed to educating health professionals on the newfound systemic health effects of the gut microbiota, helping them to provide innovative, evidence-based natural medicines for the management of some of humanity's most prevalent and chronic health concerns. Biome also develops, licenses and distributes a scientifically formulated, organic nutraceutical range, Activated Nutrients® and a sports performance and recovery range, Activated X Performance®, which is made exclusively for professional athletes. For more information visit: www.biomeaustralia.com Investor Relations Jo Power +61 432 227 123 corporate@biomeaustralia.com Forward looking statements This release may contain forward looking statements, including but not limited to projections, guidance on future revenues, earnings, other potential synergies and estimates and the future performance of Biome (Forward Looking Statements). Forward Looking Statements are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance. Actual results, performance or achievements may differ materially from those expressed or implied in such Forward Looking Statements and any projections and assumptions on which these Forward Looking Statements are based. Such statements may assume the success of Biome's business strategies. You are cautioned not to place undue reliance on Forward Looking Statements. The Forward Looking Statements are based on information available to Biome as at the date of this release. Any Forward Looking Statements containing forward looking financial information provided in this release is for illustrative purposes only and is not represented as being indicative of Biome's views on its future financial condition and/or performance. The historic financial information for the September 2021 financial quarter and revenue figures for October and November 2021 have not been audited or reviewed by Biome's auditors. Such information should not be taken as a guide for future performance. Nothing in this release is a promise or representation as to the future. No representation or warranty, express or implied, is made as to the accuracy, likelihood of achievement or reasonableness of any Forward Looking Statements contained in this release. Except as required by law or regulation (including the ASX Listing Rules), Biome does not undertake to provide any additional or updated information whether as a result of a change in expectations or assumptions, new information, future events or results or otherwise. To the maximum extent permitted by law, Biome excludes and expressly disclaims all liabilities in respect of, and makes no representation or warranty, express or implied as to the fairness, currency, accuracy, reliability or completeness of information in this release or the accuracy, likelihood of achievement or reasonableness of any Forward Looking Statements (or any event or results expressed or implied in any Forward Looking Statements) contained in, implied by, the information in this release or any part of it, or that this release contains all material information about Biome or which a prospective investor or purchaser may require in evaluating a possible investment in Biome or acquisition of securities in Biome. Investors are strongly cautioned not to place undue reliance on Forward Looking Statements, particularly in light of the current economic climate and the significant volatility, uncertainty and disruption caused by the Covid-19 pandemic.